Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

KRAS polymorphisms are associated with survival of CRC in Chinese population.

Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH.

Tumour Biol. 2016 Apr;37(4):4727-34. doi: 10.1007/s13277-015-4314-1. Epub 2015 Oct 29.

PMID:
26515332
2.

XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.

Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang ZH.

Mutagenesis. 2015 May;30(3):441-9. doi: 10.1093/mutage/geu088. Epub 2015 Feb 17.

PMID:
25690281
3.

KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.

Yang M, Xiao X, Xing X, Li X, Xia T, Long H.

PLoS One. 2017 Mar 22;12(3):e0174140. doi: 10.1371/journal.pone.0174140. eCollection 2017.

4.

MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.

Schneiderova M, Naccarati A, Pardini B, Rosa F, Gaetano CD, Jiraskova K, Opattova A, Levy M, Veskrna K, Veskrnova V, Buchler T, Landi S, Vodicka P, Vymetalkova V.

Mutagenesis. 2017 Oct 17;32(5):533-542. doi: 10.1093/mutage/gex026.

PMID:
29048575
5.

A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.

Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, Xu GH, Gao LB.

Tumour Biol. 2014 Jan;35(1):831-5. doi: 10.1007/s13277-013-1114-3. Epub 2013 Aug 24.

PMID:
23975373
6.

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.

Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12.

7.

Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.

Fernández-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, González-Aguilera JJ.

Int J Colorectal Dis. 2010 Feb;25(2):141-51. doi: 10.1007/s00384-009-0779-y. Epub 2009 Aug 11.

PMID:
19669769
8.

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.

Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11.

9.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
10.

DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.

Liu D, Wu HZ, Zhang YN, Kang H, Sun MJ, Wang EH, Yang XL, Lian MQ, Yu ZJ, Zhao L, Olopade OI, Wei MJ.

Mol Carcinog. 2012 Oct;51 Suppl 1:E83-93. doi: 10.1002/mc.21862. Epub 2011 Dec 27.

PMID:
22213216
11.

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.

Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB.

Genet Mol Res. 2015 Dec 14;14(4):16913-20. doi: 10.4238/2015.December.14.19.

12.

KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.

Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS.

J Vasc Interv Radiol. 2015 Aug;26(8):1102-11. doi: 10.1016/j.jvir.2015.05.032.

PMID:
26210240
13.

A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.

Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, Jia J, Gao LB.

Tumour Biol. 2013 Oct;34(5):3159-63. doi: 10.1007/s13277-013-0885-x. Epub 2013 Jun 2.

PMID:
23729275
14.

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH.

BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534.

15.
16.

Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer.

Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C, Qu F, Li Y, Bao G, Chen Z, Xing J.

Cancer. 2012 Feb 15;118(4):937-46. doi: 10.1002/cncr.26348. Epub 2011 Jul 19.

17.

Association of single nucleotide polymorphisms in the coding region of Bcl-2 with the occurrence and prognosis of colorectal cancer: A case-control study.

Huang B, Liu X, Sun C, Wang L, Yang L.

Cancer Biomark. 2017;18(4):433-439. doi: 10.3233/CBM-160378.

PMID:
28106544
18.

GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.

Xu K, Wang J, Gao J, Di J, Jiang B, Chen L, Wang Z, Wang A, Wu F, Wu W, Shen L, Su X.

Oncol Rep. 2016 Sep;36(3):1672-8. doi: 10.3892/or.2016.4961. Epub 2016 Jul 21.

PMID:
27460045
19.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

20.

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.

Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2577-2583. Epub 2016 Sep 12.

PMID:
27620744

Supplemental Content

Support Center